Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Expanding anti-CD38 immunotherapy for lymphoid malignancies

Fig. 4

Potent effector function of CD38-CAR T cells against T-ALL and NKTCL in vitro. A CD38 expression in T-ALL (MOLT-4) and NKTCL (NK-92, HANK-1, KHYG-1, NK-YS, YT, SNK-6) cell lines by flow cytometry. B The cytotoxic activity of CD4+ and CD8+ CD38-CAR T cells. T cells were co-cultured with T-ALL and NKTCL cells and K562 (negative control) with stably expressed fLuc for 4 and 20 h, respectively, at various E:T ratios. C Evaluation of CD107a expression by flow cytometry. Effector cells were co-cultured with target cells for 6 h at a 2:1 E:T ratio. D Proliferation assessed by absolute cell number and CellTrace™ far-red proliferation dilution after 5 days of co-culture of effector and target cells. Assays were performed with effector cells and irradiated target cells at a 1:2 E:T ratio without the addition of exogenous cytokines. E Secretion of IL-2, IFN- γ, TNF- α, and perforin from effector cells by ELISA. Assays were performed using supernatants obtained after a 20 h co-culture of effector and target cells at a 2:1 E:T ratio

Back to article page